Medical network - March 1 API prices, more strict quality supervision policy, environmental protection tax policy strictly, even will jointly push the high cost of drug companies, in 2017, the drug price increase is a big probability event, out of stock risk is more and more big.
"Since last year, part of pharmaceutical raw materials prices have started to increase." On February 27th, a drug firms of hubei province chief reporter revealed to the 21st century economy. The rise in prices of raw materials, however, has not appeared in the actual sales side, most of the drugs did not rise in price, even the cost price of some drugs are more than the retail price, selling price.
To this year, the industry's expectations of drug prices, "at present, although there are very few drug firms put forward price, but almost every drug firms to negotiate a new cooperation mentioned the possibility of going to rise in price." Hubei another medicine circulation enterprises chief also said.
Form such expectations are the main reason is that the present carrying out the drug evaluation consistency rules, strict quality supervision, to change, even environmental protection policy, "the policy of gradually advancing, pushing up the cost of drug firms to a certain extent, thus lead to inflationary expectations." Think, head of the medicine circulation enterprises, follow-up may rewrite medicine industry pattern.
The government, however, the current policy thinking and control drug prices rise, drug firms rising costs push up prices, terminal retail price increases is limited, seems to be an unanswered problem.
Temporarily not rising terminal pharmaceuticals market
Fook on church near at zhongnan university of economics and law wuhan in the pharmacy, the assistant is inventory goods, "since last year's tax policy may change after a lot of drug price is indeed improved." The pharmacy assistant told reporter in the 21st century economy, for example, some common, such as colds, fever, diarrhea medicine prices have improved, general gains for the carton few cents to a few dollars, but most of the drugs price no change.
However, in the production process, many API prices have started to increase.
, head of the drug firms to reporters, according to a "hangs varieties detail" to show so far, a total of 41 kinds of drug price upside down, one of the human blood albumin 購進(jìn)價 is 450 yuan, and the hanging WangJia is 378 yuan, become the largest drug hangs spread sheet is tasted. In addition, a kind of drugs called ace magnesium omeprazole enteric-coated metformin hydrochloride, upside down spreads reached 10 yuan.
Drug prices down is the main reason of the API prices, on the last two sessions have representative proposed, API monopoly is the main reason cause drug prices, such as heart disease of digoxin tablets, 10 times have soared.
Upside down and cause some cheap life-saving medicine out of the market in succession.
Shandong, Seth nichle pharmaceutical group of clinical inspection commissioner for the 21st century business herald reporters that used cheap drugs such as liquorice tablets, erythromycin ointment, periodontal spirit, calcium gluconate and chlorpheniramine maleate, low prices, profits thin, if raw material price again, this kind of cheap medicine no profit space, were forced to withdraw from the market, have taken their composition similar to that of imported drugs or high prices. The delisting of cheap life-saving medicine makes these products in short supply, some of this is not cheap substitute drugs are more in demand, prices will grow.
"For now, is steady, the overall volatility." Head of one of wuhan's alcon pharmacy told reporter in the 21st century economy, it is understood that some of the company's recent drug in a slight rise in price at the same time, some drugs have on sale.
"From the perspective of the drug companies of this year to discuss cooperation, although the current drug price has yet to rise, but the price is more." The circulation of drug companies, said an official with the price later.
Increase the power
Inflationary expectations from drug companies constantly pushed up costs, in addition to the rise in raw materials, 2017, will face a variety of price increases.
On May 1, 2016, our country comprehensively advancing to increase "camp". To increase in the long run, "camp" seems to pharmaceutical companies to reduce costs, but the reality of China, "camp to increase inevitably bring tax scrutiny." This means that the medicine circulation enterprises will increase costs, this difference may be reflected in the terminal in drug pricing.
Reporters from wuhan who pharmacy has also confirmed that tax policy changes since last may, a lot of drug prices do have improved.
Increasingly strict quality supervision, will also push up the cost of drug firms.
Last December, the national food administration of drug safety evaluation center on the registration of listed pharmaceutical production process information to solicit comments template public notice, the production process with the declaration and can not complete the full research products, close immediately.
Before, many small and medium-sized and even large drug companies to save costs, is to simplify the production process, tamper with the production process, such as not compliance, is expected to have a large number of drug companies exposed under inspection.
In addition, in July last year, the new revised "drug-handling quality management norms" (hereinafter referred to as "the new GSP") effect, "according to the requirements of the new GSP, whether the drug warehouse or office space, have put forward higher request, for enterprise cost some needs up to tens of millions of dollars." Said, head of the drug firms, for instance, before the relatively cheap coal replaced by natural gas energy requirement, enterprise to be compliance to continue as a going concern, this part of the cost must be spending, and compared to 2015, the company costs rose at least 20% in 2016.
Drug consistency evaluation in advance, but also another factor driving up costs of drug companies. "In accordance with the provisions, must through consistency evaluation of drug although the proportion is not big, but even for the small number of drugs, the management of the enterprises also need to pay fees." The current drug firms head said.
Finally, the implementation of environmental protection to have entered the countdown.
December 25 last year by the law of the People's Republic of China environmental protection tax law will take effect on January 1, 2018. Previously, due to the environmental problems of shijiazhuang shiyao, north China pharmaceutical well-known pharmaceutical companies such as I can remember all the news. Environmental cost is high, there will be a large number of enterprises to make production for the time being.
"Environmental protection and emission permits system of the cost of production is likely to improve drug firms. In order to make the production process in conformity with the requirements of environmental protection, companies will need to improve process or buying advanced environmental protection equipment, if the cost is more, will be reflected on the ex-factory price", hubei pharmaceutical business association secretary-general Yu Kaixiong said, at present, although the distance between implementation and a period of time, there must be a transition, but environmental regulation pharmaceutical enterprise in 2017 or the need to plan ahead and prepare. However, the current reform of general principle is to control drug prices. National bureau of statistics data show that in 2016 China's pharmaceutical industry revenue and profit growth of 9.7% and 13.9% respectively, compared with 2015, 0.6 and 1% respectively. China merchants securities statistics for 2016 domestic pharmaceutical listed company earnings forecast, forecast domestic pharmaceutical listed companies in 2016 net profit growth of 20% or so.
"Compared to the past, drug companies profit margins up slightly, but as the superposition of all kinds of cost, subsequent drug firms the sustainability of earnings problem will be a business issue." The medicine circulation enterprises head said.
|
